Differently, in this paper, we propose a new type of SOD task, termed Arbitrary Modality SOD (AM SOD). The most prominent characteristics of AM SOD are that the modality types and modality numbers ...

Sage Therapeutics (SAGE) stock falls as Huntington's Disease candidate dalzanemdor fails in Phase 2 trial. Read more here.

Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in various combinations and emerging therapeutic modalities. Together ...

To fully harness and embody their Jupiterian strengths and wisdom, exploring the best crystals for Sagittarius can be ...

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary ...

After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has ...

The Phase II DIMENSION study of Sage's dalzanemdor failed to meet its primary and secondary endpoints for treating Huntington ...

TD Cowen lowered the firm’s price target on Sage Therapeutics (SAGE) to $9 from $10 and keeps a Hold rating on the shares. The firm noted they ...

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating ...

Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive ...

The dream may be to have generative AI write RTL, but text is only one of the necessary things AI must understand to help ...

Sage Therapeutics (SAGE) announced topline results from the Phase 2 DIMENSION Study of dalzanemdor, or SAGE-718, in participants with cognitive ...